Newmeta G16 Injection

Adult dosage

The dosage is to be determined based on the patient's condition, caloric expenditure, weight, age, metabolic capacity, and any additional caloric or protein supply via oral or gastrointestinal means. The maximum recommended dose should not be exceeded. The undiluted drug has a high osmotic pressure and can only be administered via central venous access; however, if sufficiently diluted, peripheral venous infusion can be permitted. The infusion rate should gradually increase during the first hour of administration and decrease gradually during the last hour of administration.

Caution is necessary when administering this drug to premature and low birth weight infants. These infants have a reduced ability to remove lipids from the blood, which may lead to elevated levels of free fatty acids when this drug is administered intravenously. In cases of premature infants with severe respiratory conditions, the lipid components of this drug may accumulate in the pulmonary vasculature, leading to potentially fatal outcomes, so it is advisable to avoid its use. This drug should not be administered to patients with allergies to eggs, soybeans, peanuts, or congenital amino acid metabolism disorders, or to patients with abnormally high electrolyte levels. Additionally, in newborns aged 28 days or younger, concurrent administration with ceftriaxone is contraindicated, as it poses risks. It is also prohibited in patients with severe hyperglycemia, hyperlipidemia, or severe lipid metabolism disorders. In patients with pulmonary edema or heart failure, administration should be done cautiously while monitoring fluid status closely. Patients with renal failure should also carefully monitor fluid and electrolyte status, and patients with severely impaired liver function should regularly check liver function values during administration. Patients with endocrine and metabolic disorders may experience metabolic anomalies if the nutritional provision is not tailored to the patient's needs or metabolic capacity is insufficiently assessed, so caution is warranted. Allergic reactions may occur during administration of this drug; should symptoms such as fever, rash, or respiratory distress occur, administration should be stopped immediately. Also, because it contains corn-derived glucose, it should be used cautiously in patients allergic to corn. This drug can cause tissue damage and skin necrosis due to extravasation during intravenous administration, so it must be properly diluted and infused through a central vein. Peripheral vein administration can be risky. During administration, blood glucose, electrolytes, liver and kidney function, coagulation status, etc. should be regularly tested in order to detect abnormalities early. In particular, magnesium levels should be periodically checked to prevent hypermagnesemia, and the infusion rate should be adjusted or stopped if necessary. In case of overdose, symptoms such as vomiting, tremors, electrolyte abnormalities, and fluid overload may occur, so administration should be stopped immediately and appropriate treatment should be provided. There is no antidote for overdose of this drug, so symptomatic supportive treatment is necessary. This drug may interact with other calcium-containing preparations or specific medications, so it is essential to consult healthcare providers before administration. Safety data on pregnant or lactating women is insufficient, thus risks and benefits should be carefully evaluated when using it. Finally, this drug must be used immediately after opening, and storage or reuse should be avoided. Additionally, aseptic techniques and catheter management should be observed to prevent infections during administration.

Serious side effects

Difficulty breathing, respiratory distress, pulmonary vascular embolism, accumulation of fat in pulmonary vessels, skin peeling, severe swelling, severe hyperglycemia, significant edema, liver abnormalities (worsening liver function, cholestasis, elevation of liver enzymes), severe neurological symptoms (coma), elevated blood pressure, coagulation disorders, severe allergic reactions (hives, tightness in the chest, cold sweat, pallor), asthma attacks, seizures, confusion, visual disturbances, paralysis

Mild side effects

• Hyperglycemia
• hypercalcemia
• hypertriglyceridemia
• hyperlipidemia
• hypophosphatemia
• hyponatremia
• cholestasis
• extravasation
• skin necrosis
• soft tissue damage

This drug should be stored in a tightly sealed container, maintaining a temperature between 1 and 25 degrees Celsius. It is also important not to freeze the drug.

Appearance

The amino acid solution and sugar solution are colorless to pale yellow transparent liquids, while the lipid solution is a homogeneous cloudy liquid separated into three spaces within a single transparent plastic bag by two partitions.

Package unit

500 ml (Amino Acid Solution 221ml, Sugar Solution 155ml, Lipid Solution 124ml) / Bag